The Valley Desk

ArticleJHLT openPublished

Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
JHLT open
Published
Subject terms
Mortality; Survival; Endothelin receptor antagonist; Pulmonary Arterial Hypertension; Phosphodiesterase-5 Inhibitor; Macitentan; Upfront Combination Therapy
PubMed ID
41568020
PubMed Central ID
PMC12818237
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal